NasdaqGS:ZYMEBiotechs
Does Zymeworks’ HERIZON-GEA-01 Win And Milestone Potential Change The Bull Case For ZYME?
In early January 2026, Zymeworks reported positive Phase 3 HERIZON-GEA-01 results for its HER2-targeted therapy Ziihera in advanced gastroesophageal adenocarcinoma, alongside a series of leadership changes including new board and executive appointments and key retirements.
A distinctive angle in this news is that the HERIZON-GEA-01 data could unlock up to US$440.0 million in potential approval-related milestones for Ziihera across the US, Europe, Japan, and China, adding financial...